Olezarsen
Payments companies reported to CMS as associated with Olezarsen. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Olezarsen, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Olezarsen
These are the largest totals companies reported as associated with Olezarsen. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Seth Baum | Boca Raton, FL | Cardiovascular Disease | $18,460.27 |
| Nicholas Marston | Boston, MA | Cardiovascular Disease | $14,556.27 |
| Andrew Freeman | Denver, CO | Cardiovascular Disease | $14,351.15 |
| Paul Duell | Portland, OR | Endocrinology, Diabetes & Metabolism | $14,313.54 |
| Savitha Subramanian | Seattle, WA | Endocrinology, Diabetes & Metabolism | $14,119.02 |
| Francisco Lopez-Jimenez | Rochester, MN | Cardiovascular Disease | $13,742.46 |
| Aman Rajpal | Oakland, CA | Endocrinology, Diabetes & Metabolism | $13,558.54 |
| Danny Eapen | Houston, TX | Cardiovascular Disease | $13,116.30 |
| James Trippi | Indianapolis, IN | Cardiovascular Disease | $12,787.07 |
| Helena Rodbard | Rockville, MD | Endocrinology, Diabetes & Metabolism | $11,749.95 |
Prescribed Olezarsen?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.